<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02964715</url>
  </required_header>
  <id_info>
    <org_study_id>ERF-4</org_study_id>
    <nct_id>NCT02964715</nct_id>
  </id_info>
  <brief_title>The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes</brief_title>
  <official_title>The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Malaya</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-Alcoholic Fatty Liver Disease( NAFLD) is common in patients with type 2 diabetes.
      Empagliflozin, an FDA-approved oral medication used to treat type 2 diabetes, has been shown
      to reduce production and deposition of fat in the liver in animal experiments. There is
      little published evidence that this is so in Asian patients with type 2 diabetes. The
      investigators designed this pilot study to determine if use of empagliflozin for 6 months in
      patients with type 2 diabetes can improve scan, blood marker and biopsy features of NAFLD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Empagliflozin, an FDA-approved SGLT2 (Sodium glucose transporter 2) inhibitor used to treat
      type 2 diabetes, has been shown to reduce hepatic de novo lipogenesis and hepatic steatosis
      in animal models. There is little published evidence that this is so in Asian patients with
      type 2 diabetes. The investigators designed this open label proof of concept trial to
      determine if use of empagliflozin for 6 months in patients with type 2 diabetes can improve
      biomarkers and histological features of biopsy proven NAFLD.

      Hypotheses

      1. 6 months of empagliflozin will result in improved histology on liver biopsy in type 2 dm
      patients with NAFLD

      2.6 months of empagliflozin will result in changes in liver enzymes, adipocytokines and FGF
      levels in type 2 dm patients with NAFLD

      3.6 months of empagliflozin will result in improved liver stiffness measurement in type 2 dm
      patients with NAFLD

      Study protocol

      This is a prospective open-label proof-of-concept study. The investigators plan to recruit 25
      Asian patients with biopsy-proven NASH and type 2 diabetes and commence them on empagliflozin
      25 mg daily for 6 months. Upon recruitment clinical information will be obtained via an
      interview and use of a structured questionnaire. Anthropometric measurements will be obtained
      at baseline and 6 months. A repeat liver biopsy will be performed after 6 months of
      empagliflozin therapy. MRI and fibroscan of the liver will be conducted at baseline and 6
      months. Fasting blood samples will be drawn for glucose, insulin, c-peptide, triglyceride,
      HDL, LDL, total cholesterol, NEFA(non-esterified fatty acid), HbA1c , liver function
      test(including albumin, AST, ALT, gamma GT, uric acid, inflammatory markers, FGF(fibroblast
      growth factor) and other biomarkers at baseline and 6 months.

      Patients will be reviewed by a physician at 1 month and 6 months for development of any
      potential adverse events while on empagliflozin therapy.

      Patients will be instructed not to make any significant changes to diet and lifestyle in
      these 6 months in order to assess to full effect of the intervention with no possible
      confounding factors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in histological Grade as evaluated with Non-alcoholic Steatohepatitis Clinical Research Network Scoring System</measure>
    <time_frame>baseline, 6 months</time_frame>
    <description>liver biopsy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum FGF 21</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>blood test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fibroscan and elastography measure of liver stiffness</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Liver enzymes</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>blood test - AST,ALT, gamma GT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in steatosis</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>histological</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lobular inflammation</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>histological</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ballooning</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>histological</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fibrosis</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>histological</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic outcome -HbA1c</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic outcome - fasting NEFA</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic outcome - fasting Tg</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum FGF 19</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum adiponectin</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum IL-6</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum TNF alpha</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum uric acid</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MRI features of NASH</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>serum concentration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Type2 Diabetes</condition>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>Interventional arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with NAFLD and Type 2 Diabetes prescribed 25mg empagliflozin(JARDIANCE) daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>25 mg daily for 6 months</description>
    <arm_group_label>Interventional arm</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  biopsy proven NASH

          -  Type 2 DM

          -  HbA1c :&gt;6.5%

          -  BMI &lt; 45kg/m2

          -  Any anti-diabetic agent except SGLT2 inhibitors, TZDs(thiazolidinediones),
             DPP4(Dipeptidyl peptidase4) inhibitors and GLP1 RAs(Glucagon-like Peptide 1-Receptor
             Agonists)

        Exclusion Criteria:

          -  eGFR &lt;45 ml/min

          -  structural and functional urogenital abnormalities, that predispose for urogenital
             infections

          -  Investigational product use in the last 6 months

          -  SGLT2 inhibitor, TZD, DPP4 inhibitor and GLP1 RA use within the past 6 months

          -  DKA(Diabetic Ketoacidosis) or HHS(Hyperosmoloar Hyperglycaemic Syndrome) within the
             last 6 months

          -  Pregnancy

          -  Presence of major contraindications to magnetic resonance imaging (cardiac pacemakers,
             claustrophobia, foreign bodies and implanted medical devices with ferromagnetic
             properties).

          -  Liver cirrhosis

          -  Type 1 diabetes

          -  Severe uncorrected insulin insufficiency

          -  Significant alcohol intake

          -  HIV infection

          -  Use of Traditional Chinese Medication or alternative therapies

          -  Coexisting causes of chronic liver disease - chronic viral hepatitis(B &amp; C),
             autoimmune liver disease, hemochromatosis, Wilson's etc.

          -  Use of medications associated with steatosis eg. Methotrexate, anticonvulsants,
             antiretroviral therapy etc.

          -  h/o stroke

          -  Steroid therapy

          -  Endogenous Cushing's

          -  Familial hypertriglyceridemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shireene R Vethakkan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Malaya</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shireene R Vethakkan, MD</last_name>
    <phone>0162093355</phone>
    <email>shireene.vethakkan@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wah K Chan, MRCP</last_name>
    <phone>0163655232</phone>
    <email>wahkheong2003@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Malaya</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Wilayah Persekutuan</state>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shireene R Vethakkan, MD</last_name>
      <phone>0162093355</phone>
      <email>shireene.vethakkan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Wah K Chan, MRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <reference>
    <citation>Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2016 Mar 17;374(11):1094. doi: 10.1056/NEJMc1600827.</citation>
    <PMID>26981940</PMID>
  </reference>
  <reference>
    <citation>Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A &quot;Thrifty Substrate&quot; Hypothesis. Diabetes Care. 2016 Jul;39(7):1108-14. doi: 10.2337/dc16-0330.</citation>
    <PMID>27289126</PMID>
  </reference>
  <reference>
    <citation>Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013 Sep 5;715(1-3):246-55. doi: 10.1016/j.ejphar.2013.05.014. Epub 2013 May 23.</citation>
    <PMID>23707905</PMID>
  </reference>
  <reference>
    <citation>Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism. 2016 Aug;65(8):1096-108. doi: 10.1016/j.metabol.2016.01.001. Epub 2016 Jan 11. Review.</citation>
    <PMID>26856933</PMID>
  </reference>
  <reference>
    <citation>Ballestri S, Nascimbeni F, Romagnoli D, Lonardo A. The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res. 2016 Oct;46(11):1074-1087. doi: 10.1111/hepr.12656. Epub 2016 Mar 30.</citation>
    <PMID>26785389</PMID>
  </reference>
  <reference>
    <citation>Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr. 2016 Jul 26;8:45. doi: 10.1186/s13098-016-0169-x. eCollection 2016.</citation>
    <PMID>27462372</PMID>
  </reference>
  <reference>
    <citation>Alisi A, Ceccarelli S, Panera N, Prono F, Petrini S, De Stefanis C, Pezzullo M, Tozzi A, Villani A, Bedogni G, Nobili V. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease. PLoS One. 2013 Jun 26;8(6):e67160. doi: 10.1371/journal.pone.0067160. Print 2013.</citation>
    <PMID>23840612</PMID>
  </reference>
  <reference>
    <citation>Dushay JR, Toschi E, Mitten EK, Fisher FM, Herman MA, Maratos-Flier E. Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Mol Metab. 2014 Oct 8;4(1):51-7. doi: 10.1016/j.molmet.2014.09.008. eCollection 2015 Jan.</citation>
    <PMID>25685689</PMID>
  </reference>
  <reference>
    <citation>Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005 Jun;41(6):1313-21.</citation>
    <PMID>15915461</PMID>
  </reference>
  <reference>
    <citation>Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-JÃ¤rvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010 May;42(5):320-30. doi: 10.1016/j.dld.2010.01.016. Epub 2010 Mar 6. Review.</citation>
    <PMID>20207596</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2016</study_first_submitted>
  <study_first_submitted_qc>November 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <last_update_submitted>May 27, 2017</last_update_submitted>
  <last_update_submitted_qc>May 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Malaya</investigator_affiliation>
    <investigator_full_name>Shireene Vethakkan</investigator_full_name>
    <investigator_title>Associate Professor Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

